Author name: Janet Kwiatkowski

Janet Kwiatkowski has over 13 years of Regulatory Affairs and Compliance leadership and employee development experience at Director and Manager Levels at Fortune 500 and start-up companies. Janet Kwiatkowski is experienced at creating effective cross-functional teams to bring products to global markets and develop regulatory strategies aligned with business plans. Successful achieving results through creative and innovation solutions. She has led Regulatory Affairs and Compliance organizational transformations, successfully implemented regulatory strategies, developed international business markets through regulatory affairs, and created and conducted leadership and diversity training programs.

Navigating Regulatory Complexities: MAE Group’s Strategy for Market Entry with a Mobile Medical App

Goal Project goal was to research and determine regulatory strategy to market a mobile medical app as a diagnostic aid to determine level of cognitive functioning. Background A European startup company developed a mobile device app known as Standardized Mental Capacity Assessment. This app is intended as a diagnostic aid to determine level of cognitive […]

Navigating Regulatory Complexities: MAE Group’s Strategy for Market Entry with a Mobile Medical App Read More »

Regulatory Affairs, Success Stories

Mapping the Path to FDA Clearance: MAE Group’s DHF Compliance Efforts in Renal Dialysis

Goal To determine the gaps in documentation between the existing CE Technical File (and other historical design documents) and the requirements of a design history file (DHF) Background A global premier health care company provides products and services for renal dialysis has designed and manufacturers a therapy system for continuous renal replacement therapy (CRRT), intended

Mapping the Path to FDA Clearance: MAE Group’s DHF Compliance Efforts in Renal Dialysis Read More »

Regulatory Affairs, Success Stories

From Assessment to Approval: MAE Group’s Journey to CE Marking for Molecular Breast Imaging Devices

Goal The project goal was to secure CE Marking for a Molecular Breast, Imaging medical device according to the European Medical Device Directive. Background A US medical device company developed a molecular breast imaging therapy system used as an adjunct to standard mammography that measure and image the distribution of radionuclides to aid in the

From Assessment to Approval: MAE Group’s Journey to CE Marking for Molecular Breast Imaging Devices Read More »

Regulatory Affairs, Success Stories

Recall Resolution: MAE Group’s Strategic Approach to Knee Brace Safety

Goal The project goal was to lead the global recall of Post-Operative Knee Brace medical device Background A US-based orthopedic rehabilitation products company designs and manufactures, a knee brace intended to control the range of motion at the knee joint following surgeries and other structural repairs. Due to a failure in the mechanical hinge, the

Recall Resolution: MAE Group’s Strategic Approach to Knee Brace Safety Read More »

Regulatory Affairs, Success Stories

We’re Growing! MAE Consulting Expands to Europe

MAE Consulting Group of the United States and now the United Kingdom, is a business service provider specializing in offering domestic and international regulatory, clinical and compliance services to healthcare companies. With expertise in commercializing medical and in vitro diagnostic devices, MAE Consulting can market your product globally and across the Atlantic — in either direction. The new MAE office

We’re Growing! MAE Consulting Expands to Europe Read More »

MAE Consulting International

Changes expected with the Indian Medical Device Regulations

The government of India is planning to develop an in-depth regulatory framework for medical devices. The current system lacks distinctive regulatory system and medical devices are either regulated as drugs or are unregulated. Medical devices that are regulated are under the Drug Controller General of India (DCGI) within the Central Drugs Standard Control Organization (CDSCO);

Changes expected with the Indian Medical Device Regulations Read More »

Educational/Training, International Government Regulations

The Importance of Article Selection for Meeting the MedDev 2.7.1 Rev 3 Requirements

Posted By: By Donna Mitchell-Magaldi, Nerac Analyst On March 20, 2010, the revised Guideline; MedDev 2.7.1 Rev 3 Clinical Evaluation: A Guide for Manufacturers and Notified Bodies became a requirement for obtaining and maintaining a CE Mark for all classes of devices marketed in the European Union. An important component of the MedDev 2.7.1 Rev

The Importance of Article Selection for Meeting the MedDev 2.7.1 Rev 3 Requirements Read More »

Resources

Drugs and Biologics in Cosmetics – Who’s Paying Attention?

According to the Food and Drug Administration’s (FDA) website, “FDA’s legal authority over cosmetics is different from other products regulated by the agency, such as drugs, biologics, and medical devices. Cosmetic products and ingredients are not subject to FDA premarket approval authority, with the exception of color additives. However, FDA may pursue enforcement action against

Drugs and Biologics in Cosmetics – Who’s Paying Attention? Read More »

Uncategorized
Scroll to Top